These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 22432983)

  • 1. Management of opioid substitution therapy during medical intervention.
    Murnion B
    Intern Med J; 2012 Mar; 42(3):242-6. PubMed ID: 22432983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction.
    Kraus ML; Alford DP; Kotz MM; Levounis P; Mandell TW; Meyer M; Salsitz EA; Wetterau N; Wyatt SA;
    J Addict Med; 2011 Dec; 5(4):254-63. PubMed ID: 22042215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of opioid dependence in the setting of pregnancy.
    Young JL; Martin PR
    Psychiatr Clin North Am; 2012 Jun; 35(2):441-60. PubMed ID: 22640765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prevalence and correlates of buprenorphine inhalation amongst opioid substitution treatment (OST) clients in Australia.
    Horyniak D; Dietze P; Larance B; Winstock A; Degenhardt L
    Int J Drug Policy; 2011 Mar; 22(2):167-71. PubMed ID: 21112758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use and misuse of opioid replacement therapies: a Queensland study.
    Smirnov A; Kemp R
    Subst Use Misuse; 2012 Jan; 47(1):78-85. PubMed ID: 22216993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.
    Curcio F; Franco T; Topa M; Baldassarre C;
    Eur Rev Med Pharmacol Sci; 2011 Aug; 15(8):871-4. PubMed ID: 21845796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Opiate substitution treatment's cycles in a five-year followed-up cohort in ambulatory practice].
    Dupouy J; Bez J; Barsony J; Oustric S; Lapeyre-Mestre M
    Therapie; 2013; 68(3):155-61. PubMed ID: 23886460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-marketing surveillance of buprenorphine-naloxone in Australia: diversion, injection and adherence with supervised dosing.
    Larance B; Degenhardt L; Lintzeris N; Bell J; Winstock A; Dietze P; Mattick R; Ali R; Horyniak D
    Drug Alcohol Depend; 2011 Nov; 118(2-3):265-73. PubMed ID: 21565452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone.
    Sekar V; Tomaka F; Lefebvre E; De Pauw M; Vangeneugden T; van den Brink W; Hoetelmans R
    J Clin Pharmacol; 2011 Feb; 51(2):271-8. PubMed ID: 20421512
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy versus effectiveness of buprenorphine and methadone maintenance in pregnancy.
    Newman RG; Gevertz SG
    J Addict Dis; 2011 Oct; 30(4):318-22. PubMed ID: 22026523
    [No Abstract]   [Full Text] [Related]  

  • 13. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
    Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
    Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid dependence - management in general practice.
    Frei M
    Aust Fam Physician; 2010 Aug; 39(8):548-52. PubMed ID: 20877747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Should I stay or should I go?" Coming off methadone and buprenorphine treatment.
    Winstock AR; Lintzeris N; Lea T
    Int J Drug Policy; 2011 Jan; 22(1):77-81. PubMed ID: 20956077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine + naloxone: new combination. Opiate dependence: no proof of reduced risk of self-administered injection.
    Prescrire Int; 2007 Dec; 16(92):232-5. PubMed ID: 18087797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.
    Moody DE
    Expert Opin Drug Metab Toxicol; 2013 Jun; 9(6):675-97. PubMed ID: 23537174
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The diverse clinical uses of opioid receptor drugs.
    Howland RH
    J Psychosoc Nurs Ment Health Serv; 2010 May; 48(5):11-4. PubMed ID: 20415289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospital psychiatric comorbidity and its role in heroin dependence treatment outcomes using naltrexone implant or methadone maintenance.
    Ngo HT; Tait RJ; Hulse GK
    J Psychopharmacol; 2011 Jun; 25(6):774-82. PubMed ID: 20360157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ACOG Committee Opinion No. 524: Opioid abuse, dependence, and addiction in pregnancy.
    ;
    Obstet Gynecol; 2012 May; 119(5):1070-6. PubMed ID: 22525931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.